Cellectis S.A.
CLLS Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$1.05
KIRA · Stoqly’s AI analyst, in plain words
- Cellectis S.A. had $72.9M of revenue in fiscal 2025, up 75.8% on the year before. Over five years, revenue changed +7.4% a year on average.
- Its operating margin was −45.3%, up 98.1 pts: of every 100 in sales, about −45 is left after running the business.
- Cellectis S.A. lost $67.6M in fiscal 2025.
- Free cash flow was −$41.8M in fiscal 2025, −57.2% of revenue.
Market cap
$105M
P/E
—
Revenue
$72.9M
Net income
−$67.6M
Free cash flow
−$41.8M
Operating margin
−45.3%
Cellectis S.A. in 30 seconds · fiscal 2025
Are sales growing?
+75.8%
Yes. Sales grew 75.8% last year.
Does it make a profit?
−92.7%
No. It lost money last year.
Does profit turn into cash?
−57.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Cellectis S.A. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 20, 2026
- Legal name
- Cellectis S.A.
- CIK
- 0001627281
Cellectis S.A. · CLLS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $30.3M | $19.2M | $0.8M | $41.5M | $72.9M |
| Revenue growth | −40.6% | −36.8% | −96.1% | 5,397.4% | 75.8% |
| Gross margin | 93.9% | 90.8% | 2.4% | 100.0% | 100.0% |
| Operating margin | −341.0% | −467.7% | −12,887.7% | −143.5% | −45.3% |
| Net income | −$114M | −$106M | −$101M | −$36.8M | −$67.6M |
| Net margin | −376.3% | −553.6% | −13,385.3% | −88.6% | −92.7% |
| Diluted EPS | −$2.55 | −$2.33 | −$1.77 | −$0.41 | −$0.67 |
| Cash | |||||
| Cash from operations | −$105M | −$87.4M | −$24.7M | $23.0M | −$39.4M |
| Capital expenditure | $18.5M | $2.4M | $1.1M | $2.6M | $2.4M |
| Free cash flow | −$123M | −$89.9M | −$25.8M | $20.4M | −$41.8M |
| FCF margin | −405.7% | −468.8% | −3,419.7% | 49.2% | −57.2% |
| Share count change | 5.5% | 1.6% | 25.2% | 58.9% | 10.7% |
| Debt and strength | |||||
| Cash and short-term investments | $186M | $93.2M | $137M | $143M | $61.5M |
| Shareholders' equity | $221M | $118M | $84.7M | $131M | $75.9M |
| Current ratio | 4.6x | 2.5x | — | — | — |
| Interest coverage | −281.2x | −241.7x | −2.4x | −2.8x | −0.6x |
| Returns and quality | |||||
| Return on equity | −45.2% | −62.6% | −99.7% | −34.1% | −65.3% |
| Return on tangible equity | −51.6% | −90.0% | −119.3% | −28.3% | −89.7% |
| Piotroski F-score | 1 | 1 | 2 | 5 | 2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cellectis S.A. · CLLS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.05 a share, the company is worth $105M.
Source: SEC EDGAR XBRL filings (CIK 0001627281). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.